Abstract Details

Title Cardiac Sympathetic Function in the Patients with Amyotrophic Lateral Sclerosis: An Analysis Using Cardiac I-123-MIBG Scintigraphy

Topic Anterior Horn

Presentation(s) P06 - (-)

Poster/Presentation
Number 135

Objective

Background BACKGROUND: ALS is the most serious form of degenerative motor neuron disease in adults, characterized by upper and lower motor neuron degeneration, skeletal muscle atrophy, paralysis, and death. Some respiratory-dependent ALS patients die from sudden cardiac arrest or anoxic encephalopathy following circulatory collapse. The cause may be associated with sympathetic hyperactivity. However, it is few report of cardiac sympathetic function in ALS patients. I-123-metaiodobenzylguanidine (MIBG) scintigraphy is a diagnostic method for demonstration of cardiac sympathetic function. We studied cardiac sympathetic function in ALS patients using the cardiac I-123-MIBG scintigraphy.

Design/Methods DESIGN/METHODS: We investigated cardiac sympathetic function in 63 ALS patients and 10 healthy volunteers. Cardiac sympathetic function was estimated by the I-123-MIBG scintigraphy [heart / mediastinum ratio (H/M ratio) in early phase and delayed phase, washout ratio (WR)] at the time of diagnosis. Informed consent was obtained from each subject prior to participation in this study.

Results RESULTS: 1) WR of cardiac I-123-MIBG scintigraphy was significantly increased in ALS patients as compared to controls (p<0.05). 2) ALS patients with increased WR of cardiac I-123-MIBG scintigraphy has significantly higher progression rate as compared to those with normal WR (p<0.05).

Conclusions CONCLUSIONS: These results demonstrated that ALS patients in early stage have sympathetic hyperactivity, because increased WR of cardiac I-123-MIBG scintigraphy indicates cardiac sympathetic hyperactivity. ALS patients may be under chronic cardiac sympathetic hyperactivity which associates with sudden cardiac death and stress induced cardiomyopathy. Increased WR of cardiac I-123-MIBG scintigraphy may be one of predictive factor in ALS patients.

Authors/Disclosures
Yuji Tanaka, MD, PhD (Aichi University of ��ɫ��) PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Peter A. Calabresi, MD, FAAN (Johns Hopkins University)	Dr. Calabresi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Calabresi has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Idorsia. An immediate family member of Dr. Calabresi has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MyMD. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Myelin Repair Foundation. The institution of Dr. Calabresi has received research support from Genentech. Dr. Calabresi has received publishing royalties from a publication relating to health care. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving as a Study Section Member with NIH. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving as a Grant reveiwer with Myelin Repair Foundation. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving as a Speaker for CME with NYAS. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Academic CME.
	No disclosure on file
Anthony Polazzo	No disclosure on file
Isao Hozumi, MD, PhD (Gifu Pharmaceutical University)	No disclosure on file
Takashi Inuzuka, MD, FAAN (Gifu Municipal Hospital)	No disclosure on file

��ɫ����

��ɫ����

��ɫ��

��ɫ��